Applied Data Research Analyzes Emerging Technologies, Evolving Opportunities for the Next Generation of Cardiovascular Stents

Drug-eluting stents are just as safe and effective as traditional bare-metal stents when used in routine clinical practice, according to a new study by researchers at Rhode Island Hospital. Their findings are published in the November 20th issue of the Journal of the American College of Cardiology.

A revolutionary, new biomaterial, developed at the New Jersey Center for Biomaterials (NJCBM) at Rutgers University, has moved from the lab bench to field testing in record time. This achievement, a product of a breakthrough methodology in biomaterials discovery, is the enabling technology behind a coronary stent undergoing its first-in-human clinical trial in Germany and in Brazil.

New data reported at the 30th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions (SCAI), May 9-12, 2007, in Orlando, FL, will offer clues to the fate of a new-generation drug-eluting stent that is vying for a place in the treatment of coronary artery disease.